Inflammatory Bowel Diseases
42 treatments and conditions followed through the public trial records. Not medical advice.How a status is set
Lists this condition and the narrower ones beneath it. A condition is not a diagnosis.
Treatments and conditions
| Treatment and condition | Where it stands | Trials |
|---|---|---|
| AC-101 for colitis, ulcerative | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Adalimumab-800CW + Fluorescence Imaging for inflammatory bowel diseases | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| ATG + CliniMACS® TCR α/β Reagent Kit and CliniMACS® CD19 System + Prednisone/Methylprenisolone + Total Body Irradiation + RITUXIMAB + CLOFARABINE + Melphalan + PALIFERMIN for crohn disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Atorvastatin calcium trihydrate for colitis, ulcerative | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| AZD7798 for crohn disease | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Bezlotoxumab for colitis, ulcerative | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Bezlotoxumab for crohn disease | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Brivekimig for crohn disease | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Duvakitug for colitis, ulcerative | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Emvistegrast for colitis, ulcerative | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Fecal Microbial Transplantation for colitis, ulcerative | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Fecal Microbiota Transplantation for inflammatory bowel diseases | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Fluconazole for crohn disease | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Fluorescence Imaging for inflammatory bowel diseases | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Golimumab for colitis, ulcerative | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Guselkumab for colitis, ulcerative | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Guselkumab for crohn disease | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| H021 Enteric-coated Tablets High-dose Group for crohn disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| H021 Enteric-coated Tablets Low-dose Group for crohn disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Infliximab for crohn disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| infliximab (IFX) infusion; azathioprine (AZA) caps for crohn disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| infliximab (IFX) placebo infusion; azathioprine (AZA) caps for crohn disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| INT-210 Capsule for colitis, ulcerative | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Intermittent Reduced Calorie Diet (IRCD) for crohn disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| JNJ-78934804 for colitis, ulcerative | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| local co-administration of autologous ADIpose for crohn disease | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Mirikizumab for colitis, ulcerative | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Obefazimod for colitis, ulcerative | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| PALI-2108 for colitis, ulcerative | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Phentermine-Topiramate for colitis, ulcerative | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Placebo for crohn disease | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Placebo-to-match emvistegrast + Emvistegrast for colitis, ulcerative | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Risankizumab for crohn disease | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| single FMT for colitis, ulcerative | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| SPY001 for colitis, ulcerative | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| SPY001 + SPY002 for colitis, ulcerative | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| SPY001 + SPY003 for colitis, ulcerative | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| SPY002 for colitis, ulcerative | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| SPY002 + SPY003 for colitis, ulcerative | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| SPY003 for colitis, ulcerative | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Vedolizumab for colitis, ulcerative | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Vedolizumab for crohn disease | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |